Invicta Medical

Focus: Invicta Medical develops neurostimulation wearables targeting sleep apnea and metabolic diseases, operating as a medical device company from Santa Clara, CA. Company scale and maturity details are unavailable.

Metabolic Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Invicta Medical

AI assessmentNot Hiring

No open roles listed right now. Follow Invicta Medical to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

6 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Target Stimulation

Sleep Apnea

N/A

Clinical Trials (1)

NCT06635265A Study to Determine the Flow Changes And/or AHI Reduction When Stimulating Two Targets (neural And/or Muscular) for the Treatment of Obstructive Sleep Apnea in Adult Subjects

N/A

Help build intelligence for Invicta Medical

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused pipeline in sleep apnea neurostimulation with 5 active clinical trials demonstrating commitment to device innovation
Diversifying into metabolic disease space (Phase 2 regulatory T cell therapy) signals pipeline expansion beyond core indication
Early-stage position offers high autonomy and impact opportunity for professionals willing to build from foundation

Watch Out For

Zero active job openings suggest company is not actively hiring or is experiencing recruitment freeze
No revenue, employee count, funding, or financial data available—critical red flags for career stability and growth trajectory
Limited clinical trial infrastructure (only 5 trials total, none in Phase 3) indicates early development stage with years to commercialization

Generated by Claude from Invicta Medical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Hypoglossal nerve stimulation

Sleep Apnea

N/A

Clinical Trials (1)

NCT06283030Evaluation of Hypoglossal Nerve Stimulation in Humans With Obstructive Sleep Apnea

N/A

Hypoglossal nerve stimulation

Sleep Apnea

N/A

Clinical Trials (1)

NCT06283017Evaluation of the Effects of Hypoglossal Nerve Stimulation in Humans With Obstructive Sleep Apnea

N/A

Target stimulation

Sleep Apnea

N/A

Clinical Trials (1)

NCT06627127A Study to Investigate the Feasibility and Respiratory Effects of Stimulating Two Functional Targets (neural And/or Muscular) for the Treatment of Obstructive Sleep Apnea

N/A

Hypoglossal nerve and/or Ansa Cervicalis stimulation

Sleep Apnea

N/A

Clinical Trials (1)

NCT06415981Proof-of-Concept Study to Determine the Flow Changes When Stimulating Two Neural Targets for the Treatment of Obstructive Sleep Apnea

N/A

ex vivo expanded CD4+CD25+CD127- regulatory T cells

Presymptomatic Diabetes Type 1 (Stage 1)

Phase 2